CD200 Receptor Monoclonal Antibody (OX110), APC, eBioscience™

Product Specific Information

Description: The monoclonal antibody OX110 recognizes mouse CD200R also known as OX2. CD200R is an inhibitory receptor with a similar structure as its ligand, CD200, yet lacks an ITIM domain typically found in inhibitory receptors. Instead the CD200R cytoplasmic domain contains a novel phosphotyrosine binding domain NPXY, which after binding SHIP inhibits ERK, JNK and MAPK p38 pathways. In activated macrophages signaling results in inhibition of TNFalpha secretion.

Expression is restricted to hematopoietic cells: myeloid cells (monocytes, macrophages, DCs, neutrophils, mast cells and basophils) and a subset of lymphocytes as well as langerhans (LC) cells and dendritic epidermal T cells.

Applications Reported: This OX110 antibody has been reported for use in flow cytometric analysis.

Applications Tested: This OX110 antibody has been tested by flow cytometric analysis of Fc-blocked mouse thioglycolate-elicited peritoneal cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

Excitation: 633-647 nm; Emission: 660 nm; Laser: Red Laser.

Filtration: 0.2 µm post-manufacturing filtered.

Target Information

CD200R (OX2R) is a receptor for the OX-2 membrane glycoprotein, and both the receptor and substrate are cell surface glycoproteins containing two immunoglobulin-like domains. CD200R is restricted to the surfaces of myeloid lineage cells and the receptor-substrate interaction may function as a myeloid downregulatory signal. In mouse, CD200R is expressed primarily by peripheral blood monocytes and neutophils but also by other leucocytes including T-lymphocytes and mast cells. Further mouse studies of a gene related to CD200R suggests that the receptor may control myeloid function in a tissue-specific manner. Alternative splicing of CD200R results in multiple transcript variants. Diseases associated with CD200R dysfunction include primary hypertrophic osteoarthropathy.